DURECT CORPORATION (DRRX)

Company Profile

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 72 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology.

Company Info

DURECT CORPORATION

10240 Bubb Road

Cupertino CALIFORNIA 95014

P: 14087771417

CEO: James E. Brown

Employees: 72

Website: https://www.durect.com/